WuXi Biologics (Cayman) Inc. (WXIBF)
OTCMKTS · Delayed Price · Currency is USD
3.850
0.00 (0.00%)
At close: Aug 8, 2025
WuXi Biologics Revenue
In the year 2024, WuXi Biologics had annual revenue of 18.68B CNY with 9.63% growth. WuXi Biologics had revenue of 10.10B in the half year ending December 31, 2024, with 25.29% growth.
Revenue
18.68B CNY
Revenue Growth
+9.63%
P/S Ratio
6.24
Revenue / Employee
1.49M CNY
Employees
12,575
Market Cap
15.97B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 18.68B | 1.64B | 9.63% |
Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
WuXi Biologics News
- 13 days ago - WuXi Biologics' Profit Guidance Signals Rebound In China's Drug Sector - Benzinga
- 13 days ago - WuXi Biologics' Profit Guidance Signals Rebound In China's Drug Sector - Benzinga
- 4 weeks ago - WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics - PRNewsWire
- 6 weeks ago - WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL - PRNewsWire
- 2 months ago - Focus: China pharma projects disrupted by Sino-US tensions - Reuters
- 2 months ago - Hong Kong stocks waver on China’s mixed economic data - South China Morning Post
- 2 months ago - WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu - PRNewsWire
- 2 months ago - Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade - South China Morning Post